-
When I was a resident in obstetrics and gynecology in the mid-1970s, and well beyond, the dogma was that any ovarian cyst or mass in a postmenopausal woman was abnormal and required surgical resection.
-
The WHI and the WELL-HART clinical trials report that hormone therapy does not reduce the risk of coronary events or slow the progression of atherosclerosis in older women.
-
Twelve cycles of single-agent paclitaxel administered to women with advanced ovarian cancer who attain a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy significantly prolongs the duration of progression-free survival.
-
Umbilical artery Doppler as a screening test for fetal well-being in a high-risk population was associated with a decreased incidence of cesarean delivery for fetal distress compared to the nonstress testing, with no increase in neonatal morbidity.
-
In women with threatened preterm labor, sonographic measurement of cervical length helps distinguish between true and false labor.
-
Another study has shown an increase in mortality associated with the use of an oral IIb/IIIa receptor antagonist.
-
-
News from the KEEPS Study: HRT Does Not Decrease Progression of Atherosclerosis Over 4 Years of Treatment
-
In this prospective cohort study of 161 nulligravid women, there was no reliable threshold of uterine length or flexion angle measurements that were predictive of painful or difficult insertions. History of severe dysmenorrhea was the only predictor of insertion pain.
-
Barriers to guideline-adherent care for advanced ovarian cancer are impacted by geographic proximity to a high-volume hospital and travel distance. However, these geographic barriers disproportionately affect racial minorities and women of lower socioeconomic status.
